|1.||Ikeda, Kenji: 7 articles (09/2013 - 02/2010)|
|2.||Kumada, Hiromitsu: 6 articles (09/2013 - 01/2011)|
|3.||Ohue, Shoichi: 5 articles (02/2014 - 12/2010)|
|4.||Iwazawa, Jin: 5 articles (02/2014 - 12/2010)|
|5.||Mitani, Takashi: 5 articles (02/2014 - 12/2010)|
|6.||Hosaka, Tetsuya: 5 articles (09/2013 - 01/2011)|
|7.||Kawamura, Yusuke: 5 articles (09/2013 - 01/2011)|
|8.||Suzuki, Fumitaka: 5 articles (09/2013 - 01/2011)|
|9.||Saitoh, Satoshi: 5 articles (09/2013 - 01/2011)|
|10.||Suzuki, Yoshiyuki: 5 articles (09/2013 - 01/2011)|
|1.||Hepatocellular Carcinoma (Hepatoma)
02/01/2010 - "Clinical trials have shown that SM-11355 is effective for treatment of hepatocellular carcinoma. "
12/01/2013 - "To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin emulsion in unresectable hepatocellular carcinoma (HCC). "
02/01/2010 - "In this study, the safety and efficacy of SM-11355 in combination with embolizing agents were investigated in 10 patients with hepatocellular carcinoma. "
06/01/2015 - "Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma."
01/01/2014 - "Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma."
01/01/2015 - "In this patient the tumor was effectively reduced after three courses of transarterial miriplatin and subsequent radical hepatic resection. "
01/01/2011 - "Multivariate analysis revealed that response after previous TACE (pre-CR, risk ratio: 4.76; p = 0.035), tumor multiplicity (solitary, risk ratio: 9.69; p = 0.003), and injection artery (peripheral to segmental hepatic artery, risk ratio: 5.28;p = 0.040) were significant independent predictors associated with CR after TACE using miriplatin. "
01/01/2009 - "Miriplatin suspended in LPD (miriplatin/LPD) administered into the hepatic artery of this model dose-dependently inhibited the growth of Li-7 tumors without markedly enhancing body weight loss and caused a significant reduction in the growth rate at a dose of 400 microg/head compared to LPD alone. "
01/01/2011 - "Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma."
03/01/2000 - "In the groups administered 0.2 and 0.4 mg of SM-11355 or 0.4 mg of CDDP, massive necrosis was observed in the tumor tissue 1 week after drug administration, and the tumors disappeared 4 weeks after drug administration. "
01/01/2015 - "He then underwent transcatheter arterial infusion with miriplatin and iodized oil, which was effective in reducing the size of the main lesion and portal vein tumor thrombus. "
05/01/2011 - "Here, we describe transcatheter arterial infusion (TAI) using miriplatin to treat a case of advanced HCC with portal vein tumor thrombus (PVTT) refractory to TAI with epirubicin. "
05/01/2011 - "A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin."
|4.||Chronic Kidney Failure (Chronic Renal Failure)
11/01/2011 - "Although HCC patients frequently have coexisting chronic renal failure, there is no reliable data regarding clinical toxicity of miriplatin in HCC patients with chronic renal failure. "
11/01/2011 - "We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 67 HCC patients with chronic renal failure (estimated glomerular filtration rate [GFR] by the Cockcroft-Gault equation <60ml/min). "
03/01/2013 - "These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure."
03/01/2013 - "Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. "
11/01/2011 - "These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safely for HCC patients with chronic renal failure."
|5.||Neoplasm Metastasis (Metastasis)
12/28/2010 - "Thus, TACE with miriplatin can be a safe and effective therapeutic option for the treatment of neuroendocrine metastases of the liver."
12/28/2010 - "This case report describes our experience with transarterial chemoembolization (TACE) using miriplatin in 2 patients with neuroendocrine liver metastases. "
12/28/2010 - "Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver."
|2.||Ethiodized Oil (Ethiodol)
|6.||Biological Tumor Markers (Tumor Markers)
|9.||sorafenib (BAY 43-9006)
|1.||Drug Therapy (Chemotherapy)
|3.||Cardiopulmonary Resuscitation (CPR)